DE69129594D1 - Ein bifunktioneller ligand des dtpa typs - Google Patents
Ein bifunktioneller ligand des dtpa typsInfo
- Publication number
- DE69129594D1 DE69129594D1 DE69129594T DE69129594T DE69129594D1 DE 69129594 D1 DE69129594 D1 DE 69129594D1 DE 69129594 T DE69129594 T DE 69129594T DE 69129594 T DE69129594 T DE 69129594T DE 69129594 D1 DE69129594 D1 DE 69129594D1
- Authority
- DE
- Germany
- Prior art keywords
- bifunctional ligand
- dtpa
- type
- dtpa type
- bifunctional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cyclohexyl DPTA Chemical compound 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/498,319 US5124471A (en) | 1990-03-26 | 1990-03-26 | Bifunctional dtpa-type ligand |
PCT/US1991/001919 WO1991014459A1 (en) | 1990-03-26 | 1991-03-22 | A bifunctional dtpa-type ligand |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69129594D1 true DE69129594D1 (de) | 1998-07-16 |
DE69129594T2 DE69129594T2 (de) | 1998-11-05 |
Family
ID=23980556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69129594T Expired - Lifetime DE69129594T2 (de) | 1990-03-26 | 1991-03-22 | Ein bifunktioneller ligand des dtpa typs |
Country Status (10)
Country | Link |
---|---|
US (3) | US5124471A (de) |
EP (1) | EP0587555B1 (de) |
JP (1) | JPH075527B2 (de) |
AT (1) | ATE167063T1 (de) |
AU (1) | AU638127B2 (de) |
CA (1) | CA2078996C (de) |
DE (1) | DE69129594T2 (de) |
DK (1) | DK0587555T3 (de) |
ES (1) | ES2117009T3 (de) |
WO (1) | WO1991014459A1 (de) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342604A (en) * | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
US5811387A (en) * | 1990-05-15 | 1998-09-22 | Chiron Corporation | Peptoid mixtures |
US5292938A (en) * | 1992-04-13 | 1994-03-08 | Associated Universities, Inc. | Synthesis of 4-substituted-trans-1, 2-diaminocyclohexyl polyaminocarboxylate metal chelating agents for the preparation of stable radiometal antibody immunoconjugates for therapy and spect and pet imaging |
PL174721B1 (pl) * | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
DE4302287A1 (de) * | 1993-01-25 | 1994-07-28 | Schering Ag | Derivatisierte DTPA-Komplexe, diese Verbindungen enthaltende pharmazeutische Mittel, ihre Verwendung und Verfahren zu deren Herstellung |
DE4302289A1 (de) * | 1993-01-25 | 1994-07-28 | Schering Ag | Verfahren zur Herstellung C-substituierter Diethylentriamine |
EP0681484A1 (de) * | 1993-01-28 | 1995-11-15 | The Wellcome Foundation Limited | Immunreaktive reagenzien unter verwendung von heterodimeren |
IL106692A (en) * | 1993-08-13 | 1997-04-15 | Israel Atomic Energy Comm | AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING |
US5476644A (en) * | 1994-04-13 | 1995-12-19 | Sterling Winthrop Inc. | Cyclic triamine chelating agents |
DE19505960A1 (de) * | 1995-02-21 | 1996-08-22 | Deutsches Krebsforsch | Konjugat zur individuellen Dosierung von Arzneimitteln |
DE19507820A1 (de) * | 1995-02-21 | 1996-08-22 | Schering Ag | Neuartig substituierte DTPA-Derivate, deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel |
WO2000002050A1 (en) * | 1998-07-07 | 2000-01-13 | Department Of Radiation Oncology, University Of Washington | Trifunctional reagent for conjugation to a biomolecule |
US20010023288A1 (en) * | 1999-07-07 | 2001-09-20 | Wilbur D. Scott | Trifunctional reagent for conjugation to a biomolecule |
DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
EP1946775A3 (de) * | 1998-08-11 | 2008-08-06 | Biogen Idec Inc. | Kombinationstherapien für B-Zellen-Lymphome mit Verabreichung eines Anti-CD20-Antikörpers |
KR20010103655A (ko) * | 1998-11-09 | 2001-11-23 | 케네쓰 제이. 울코트 | 키메라 항-cd20항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법 |
MY155913A (en) * | 1998-11-09 | 2015-12-15 | Biogen Inc | Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US6207858B1 (en) * | 1999-03-03 | 2001-03-27 | Idec Pharmaceuticals Corporation | Regioselective synthesis of DTPA derivatives |
EP1918305A1 (de) | 1999-08-11 | 2008-05-07 | Biogen Idec Inc. | Neue klinische Parameter zur Bestimmung der hämatologischen Toxizität vor einer Strahlenimmuntherapie |
EP2264070A1 (de) | 1999-08-11 | 2010-12-22 | Biogen-Idec Inc. | Behandlung eines intermediären und hochgradigen Non-Hodgkins-Lymphoms mit Anti-CD20-Antikörper |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
RU2260217C2 (ru) | 1999-11-30 | 2005-09-10 | Скотт ШЕНТЕР | Способ получения актиния-225 и его дочерних элементов |
AUPQ582400A0 (en) * | 2000-02-24 | 2000-03-16 | Biotech Australia Pty Limited | A method of treatment and agents for use therein |
JP2004500412A (ja) * | 2000-03-31 | 2004-01-08 | アイデック ファーマスーティカルズ コーポレイション | B細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗cd20の併用 |
JP2004512262A (ja) * | 2000-06-20 | 2004-04-22 | アイデック ファーマスーティカルズ コーポレイション | 非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ |
DE10037832C2 (de) * | 2000-08-03 | 2003-08-21 | Karlsruhe Forschzent | Kontrastmittel für medizinische Diagnostik und dessen Verwendung |
EP1370292A1 (de) | 2001-01-31 | 2003-12-17 | Idec Pharmaceuticals Corporation | Verwendung von cd23 antagonisten zur behandlung von neoplastischen erkrankungen |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
CA2436180C (en) | 2001-01-31 | 2011-11-08 | Idec Pharmaceutical Corporation | Immunoregulatory antibodies and uses thereof |
AU2002307037B2 (en) * | 2001-04-02 | 2008-08-07 | Biogen Idec Inc. | Recombinant antibodies coexpressed with GnTIII |
US20040136908A1 (en) * | 2001-04-09 | 2004-07-15 | Olson William C. | Anti-cd19 immunotoxins |
WO2003000647A1 (en) * | 2001-06-22 | 2003-01-03 | Schering Ag | (ethylene)-(propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents |
EP1420688A4 (de) * | 2001-06-25 | 2005-08-31 | Us Gov Health & Human Serv | Makromolekulare abbildungsmittel für die leberabbildung |
US20030194371A1 (en) * | 2001-07-10 | 2003-10-16 | Schering Ag | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents |
CA2464239C (en) | 2001-10-23 | 2016-07-12 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
HUP0402164A3 (en) | 2001-11-16 | 2010-01-28 | Biogen Idec Inc | Polycistronic expression of antibodies |
US7368100B2 (en) * | 2002-09-06 | 2008-05-06 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same |
CA2499573A1 (en) | 2002-09-24 | 2004-04-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for convection enhanced delivery of therapeutic agents |
JP2006520194A (ja) * | 2003-01-27 | 2006-09-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Igsf9およびliv−1を使用して癌を処置するための組成物および方法 |
US8067544B2 (en) | 2003-03-19 | 2011-11-29 | Curagen Corporation | Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof |
CA2542886A1 (en) | 2003-11-05 | 2005-05-19 | Neelima M. Bhat | Enhanced b cell cytotoxicity of cdim binding antibody |
EP2962699A3 (de) | 2003-12-01 | 2016-04-06 | Immunomedics Inc. | Verbessertes verfahren zur herstellung von konjugaten von proteinen und chelatbildnern |
US20050171424A1 (en) * | 2004-01-13 | 2005-08-04 | The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services | Methods for imaging the lymphatic system using dendrimer-based contrast agents |
BRPI0517057A (pt) | 2004-11-05 | 2008-09-30 | Palingen Inc | composição para induzir ferimento de membrana celular; composição para aumentar o ferimento da membrana celular em uma célula linfóide; composição para permeabilizar uma célula; composição para induzir ferimento da membrana celular em células b; composição para aumentar o ferimento da membrana celular induzido por um anticorpo de ferimento de membrana celular; método de tratamento de um mamìfero que sofre de uma condição distinta por uma hiperproliferação de células; método para matar uma célula cancerosa; método para induzir ferimento de membrana celular em uma célula linfóide em um paciente humano; método para induzir ferimento da membrana celular; método para permeabilizar uma célula; método de purgar a medula óssea de células b malignas de um paciente com esta necessidade; estojo para determinar o limite da dose para um agente polivalente que induz o ferimento da membrana celular em um mamìfero; estojo para determinar o limite da dose para um anticorpo de ferimento de membrana celular em um mamìfero; uso de um agente polivalente de ferimento de membrana celular; e uso de um anticorpo de ferimento de membrana celular |
WO2006056443A2 (en) * | 2004-11-24 | 2006-06-01 | Aplagen Gmbh | Method for solid-phase peptide synthesis and purification |
DK1827492T3 (da) | 2004-11-30 | 2010-11-22 | Curagen Corp | Antistoffer rettet mod GPNMB og anvendelser deraf |
CN101137673B (zh) | 2005-01-05 | 2013-12-04 | 比奥根艾迪克Ma公司 | Cripto结合分子 |
WO2007084141A2 (en) * | 2005-01-24 | 2007-07-26 | Sri International | Surface-enhanced lanthanide chelates |
US20060204443A1 (en) * | 2005-03-11 | 2006-09-14 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for tumor treatment using dendrimer conjugates |
WO2007019376A2 (en) * | 2005-08-03 | 2007-02-15 | Rq Bioscience, Inc. | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
CA2629453C (en) | 2005-11-10 | 2018-03-06 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
US8288530B2 (en) * | 2006-11-06 | 2012-10-16 | The United States Of America, As Represented By The Department Of Health And Human Services | Method of preparing macromolecular contrast agents and uses thereof |
US20100092384A1 (en) * | 2007-03-19 | 2010-04-15 | The Junited States Of America As Represented By Secretary, Dept. Of Health And Human Service | Multifunctional nanoparticles and compositions and methods of use thereof |
US8535639B2 (en) * | 2007-07-17 | 2013-09-17 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging |
KR20090123171A (ko) * | 2008-05-27 | 2009-12-02 | 경북대학교 산학협력단 | Dtpa-비스-아미드 리간드를 포함하는 가돌리늄 착물과그 합성방법 |
US8420051B2 (en) | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
PL2326350T3 (pl) | 2008-09-08 | 2014-03-31 | Psma Dev Company L L C | Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych |
US8535891B2 (en) | 2008-12-30 | 2013-09-17 | Children's Medical Center Corporation | Method of predicting acute appendicitis |
WO2010078526A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
CN101914153B (zh) * | 2010-07-05 | 2012-07-04 | 吉林大学 | 一种Pb2+抗原和相应单克隆抗体及其制备方法 |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
JP6335796B2 (ja) | 2012-02-08 | 2018-06-06 | アイジーエム バイオサイエンシズ インク.Igm Biosciences Inc. | Cdim結合タンパク質及びその使用 |
JP6908964B2 (ja) | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー,エルエルシー | Psmaリガンドコンジュゲートによる併用療法 |
US20150110814A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
WO2015073896A2 (en) | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
AR099812A1 (es) | 2014-03-21 | 2016-08-17 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
WO2017214233A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
JP2019521973A (ja) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | 抗bh7−h3抗体及び抗体薬物コンジュゲート |
AU2017277534A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
MX2018015286A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Conjugados de anticuerpo anti-egfr y farmaco. |
AU2017277920A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
BR112018075626A2 (pt) | 2016-06-08 | 2019-03-19 | Abbvie Inc. | anticorpos anti-b7-h3 e conjugados de fármaco anticorpo |
MX2018015274A (es) | 2016-06-08 | 2019-10-07 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
BR112018075653A2 (pt) | 2016-06-08 | 2019-08-27 | Abbvie Inc | anticorpos anti-b7-h3 e conjugados anticorpo fármaco |
US20200147235A1 (en) | 2016-06-08 | 2020-05-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2018048879A1 (en) * | 2016-09-07 | 2018-03-15 | The Board Of Trustees Of The University Of Illinois | Metal chelators for imaging, therapeutics, and bioanalysis |
US11932694B2 (en) | 2017-04-19 | 2024-03-19 | Bluefin Biomedicine, Inc. | Anti-VTCN1 antibodies and antibody drug conjugates |
KR101931153B1 (ko) | 2017-07-03 | 2018-12-20 | 한국원자력연구원 | 아민과 선택적으로 결합하며 티오에테르 결합을 갖는 dtpa 킬레이터 및 이의 제조방법 |
WO2020106358A1 (en) | 2018-11-20 | 2020-05-28 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
IT201900003905A1 (it) * | 2019-03-18 | 2020-09-18 | Univ Degli Studi Del Piemonte Orientale “A Avogadro” | Chelanti pentadentati rigidificati utili per la marcatura [Al18F]2+ di biomolecole |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA713093A (en) * | 1965-07-06 | Dexter Martin | Complex forming polyaminopoly-carboxylic acids | |
DE1155122B (de) * | 1960-10-17 | 1963-10-03 | Geigy Ag J R | Verfahren zur Herstellung von neuen alicyclischen Polyaminopolyessigsaeuren bzw. deren komplexen Metallverbindungen |
FR1303847A (fr) * | 1961-10-16 | 1962-09-14 | Geigy Ag J R | Nouveau acides polyaminopolyacétiques, leurs complexes métalliques et leur préparation |
US4339426A (en) * | 1980-03-18 | 1982-07-13 | Regents Of The University Of California | Bleomycin analog |
US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
US4472509A (en) * | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4849505A (en) * | 1984-01-30 | 1989-07-18 | Enzo Biochem, Inc. | Detectable molecules, method of preparation and use |
US4824986A (en) * | 1985-04-26 | 1989-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Metal chelate protein conjugate |
US4899755A (en) * | 1985-05-08 | 1990-02-13 | The General Hospital Corporation | Hepatobiliary NMR contrast agents |
US4881175A (en) * | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5057302A (en) * | 1987-02-13 | 1991-10-15 | Abbott Laboratories | Bifunctional chelating agents |
-
1990
- 1990-03-26 US US07/498,319 patent/US5124471A/en not_active Expired - Lifetime
-
1991
- 1991-03-22 AU AU76565/91A patent/AU638127B2/en not_active Expired
- 1991-03-22 WO PCT/US1991/001919 patent/WO1991014459A1/en active IP Right Grant
- 1991-03-22 DK DK91908519T patent/DK0587555T3/da active
- 1991-03-22 CA CA002078996A patent/CA2078996C/en not_active Expired - Lifetime
- 1991-03-22 AT AT91908519T patent/ATE167063T1/de not_active IP Right Cessation
- 1991-03-22 JP JP3507588A patent/JPH075527B2/ja not_active Expired - Lifetime
- 1991-03-22 DE DE69129594T patent/DE69129594T2/de not_active Expired - Lifetime
- 1991-03-22 EP EP91908519A patent/EP0587555B1/de not_active Expired - Lifetime
- 1991-03-22 ES ES91908519T patent/ES2117009T3/es not_active Expired - Lifetime
-
1992
- 1992-05-11 US US07/881,049 patent/US5286850A/en not_active Expired - Lifetime
-
1993
- 1993-11-04 US US08/147,957 patent/US5434287A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1991014459A1 (en) | 1991-10-03 |
DE69129594T2 (de) | 1998-11-05 |
CA2078996C (en) | 1996-05-28 |
US5434287A (en) | 1995-07-18 |
AU7656591A (en) | 1991-10-21 |
EP0587555A4 (en) | 1994-06-08 |
DK0587555T3 (da) | 1999-03-22 |
ATE167063T1 (de) | 1998-06-15 |
US5124471A (en) | 1992-06-23 |
US5286850A (en) | 1994-02-15 |
JPH05504973A (ja) | 1993-07-29 |
CA2078996A1 (en) | 1991-09-27 |
AU638127B2 (en) | 1993-06-17 |
EP0587555B1 (de) | 1998-06-10 |
JPH075527B2 (ja) | 1995-01-25 |
ES2117009T3 (es) | 1998-08-01 |
EP0587555A1 (de) | 1994-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69129594T2 (de) | Ein bifunktioneller ligand des dtpa typs | |
DE69110657T2 (de) | Filtersackabdichtung. | |
DE3884233T3 (de) | Bifunktionelle chelatbildende Agenzien. | |
DE3672796D1 (de) | Verpackungsmaschinen des types "formen-fuellen-schliessen" in horizontaler linie. | |
DE69201671T2 (de) | Abdichtaufsätze für Filterelemente. | |
DE68908185T2 (de) | Chelat-zusammensetzung. | |
NL193194B (nl) | Stoomstrijkijzer. | |
DE58901318D1 (de) | Filtrieranordnung. | |
DE69111444T2 (de) | Gleitringdichtung. | |
DE69103762D1 (de) | Langspaltpresse. | |
DE3886088D1 (de) | Chelate von Dipyridoxylphosphat mit radioaktiven Metallen. | |
DE59102407D1 (de) | Wellenabdichtung. | |
DE59103077D1 (de) | Abnehmbare Anhängerkupplung. | |
DE68917256T2 (de) | Farbfilteranordnung. | |
DE68902546D1 (de) | Abdichtungen. | |
FR2666394B1 (fr) | Ensemble d'etancheite. | |
FR2668831B3 (fr) | Plaque double. | |
IT8324466A0 (it) | Composizioni n-cianoammidiche eloro addotti. | |
NO891706D0 (no) | Cyklodekstrinkomplekser av 5-aminoheksahydropyrimidinforbindelser. | |
IT1228962B (it) | Guarnizione per cuscinetto amovibile. | |
DE69117741T2 (de) | Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen | |
NL191929B (nl) | Filterbandpers. | |
MY131703A (en) | Complexes of the lanthanides with heterocyclic carbenes | |
FR2661336B1 (fr) | Filtre-presse a chambres. | |
IT8423547A0 (it) | Speciali organismi produttori di l-prolina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |